<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819844</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000993</org_study_id>
    <nct_id>NCT01819844</nct_id>
  </id_info>
  <brief_title>Inpatient Closed-loop Glucose Control</brief_title>
  <official_title>Subcutaneous Continuous Glucose Monitoring and Intravenous Dosing of Insulin and Dextrose for Automated Glycemic Control in the Inpatient Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test an experimental medical device designed to automatically
      control blood sugar. This device was designed for use by patients with diabetes while they
      are in the hospital, and others who may develop high blood sugar as a result of their medical
      problems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this first-in-man trial is to test the safety and efficacy of the automated,
      closed-loop control system in insulin sensitive subjects with type 1 diabetes, insulin
      sensitive subjects with type 2 diabetes (TTD &gt; 1u/kg/day), and subjects with type 2 diabetes
      and substantial insulin resistance (&lt;2 u/kg/day). The results of this study will help to
      design future studies, exploring the use of the closed-loop system for BG control in
      hospitalized patients, including those with diabetes or hyperglycemia of critical illness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Blood Glucose Over the Closed-loop Control Period, as Determined From GlucoScout Measurements.</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Carbohydrate Interventions (15 g) Delivered According to Study Protocol</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of BG Events &lt; 70 mg/dl and Nadir BG for Each as Determined Form GlucoScout Measurements</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From GlucoScout Measurements: - &lt; 70 mg/dl - 70-120 mg/dl - 70-180 mg/dl - &gt;180 mg/dl</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Blood Glucose Over the Closed-loop Control Period as Determined From the CGM Driving the Control Algorithm</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of BG Events &lt; 70 mg/dl as Determined by the CGM</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From the CGM Driving the Control Algorithm: o &lt; 70 mg/dl o 70-120 mg/dl o 70-180 mg/dl o &gt;180 mg/dl</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Dosing (u/kg)</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dextrose Dosing (g/kg)</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the CGM Device Using the GlucoScout Measurements as the Standard.</measure>
    <time_frame>12 hours</time_frame>
    <description>The Mean Absolute Relative Difference (MARD) between CGM and Glucoscout</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Closed-loop blood glucose control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed-loop blood glucose control</intervention_name>
    <description>The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
    <arm_group_label>Closed-loop blood glucose control</arm_group_label>
    <other_name>InPatient Closed-Loop Blood Glucose Control Device.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects with type 1 diabetes

          -  Age 21 to 75 with clinical type 1 diabetes for at least one year

          -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting
             insulins

          -  Total daily dose (TDD) of insulin that is &lt; 1 u/kg

        Subjects with type 2 diabetes

          -  Age 21 to 75 with clinical type 2 diabetes for at least one year

          -  Diabetes managed using NPH as the basal insulin, which may be supplemented with
             regular or rapid-acting insulin

          -  Total daily dose (TDD) of insulin that is &gt; 1 u/kg/day but &lt; 2 u/kg/day or &gt; 2
             u/kg/day

        Exclusion Criteria:

          -  Pregnancy

          -  Renal insufficiency

          -  Cancer

          -  Abnormal EKG suggestive of coronary artery disease or increased risk of malignant
             arrhythmia

          -  Acute illness or exacerbation of chronic illness at the time of the study procedure

          -  Use of non-insulin, injectable anti-diabetic medications or oral anti-diabetic
             medications other than metformin

          -  History of allergy or adverse reaction to aspirin, peptic ulcers or bleeding disorders

          -  Known history of coronary artery disease, TIA or stroke

          -  History of seizures

          -  Transaminitis

          -  Stage 2 hypertension at the time of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Russell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH Diabetes Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bionicpancreas.org</url>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>July 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2017</results_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Closed-loop blood glucose control</keyword>
  <keyword>Continuous glucose monitoring</keyword>
  <keyword>Bionic pancreas</keyword>
  <keyword>Artificial pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Closed-loop Blood Glucose Control</title>
          <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Closed-loop Blood Glucose Control</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Blood Glucose Over the Closed-loop Control Period, as Determined From GlucoScout Measurements.</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
          </group>
        </group_list>
        <measure>
          <title>Average Blood Glucose Over the Closed-loop Control Period, as Determined From GlucoScout Measurements.</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall average blood sugar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.9" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 1 subjects average blood sugar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2 subjects average blood sugar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.83" spread="21.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Carbohydrate Interventions (15 g) Delivered According to Study Protocol</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Carbohydrate Interventions (15 g) Delivered According to Study Protocol</title>
          <units>number of carbohydrate interventions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of BG Events &lt; 70 mg/dl and Nadir BG for Each as Determined Form GlucoScout Measurements</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
          </group>
        </group_list>
        <measure>
          <title>Number of BG Events &lt; 70 mg/dl and Nadir BG for Each as Determined Form GlucoScout Measurements</title>
          <units>Blood glucose values &lt; 70 mg/dl</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From GlucoScout Measurements: - &lt; 70 mg/dl - 70-120 mg/dl - 70-180 mg/dl - &gt;180 mg/dl</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From GlucoScout Measurements: - &lt; 70 mg/dl - 70-120 mg/dl - 70-180 mg/dl - &gt;180 mg/dl</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>70-180 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-120 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 70 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 180 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Blood Glucose Over the Closed-loop Control Period as Determined From the CGM Driving the Control Algorithm</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Blood Glucose Over the Closed-loop Control Period as Determined From the CGM Driving the Control Algorithm</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.8" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of BG Events &lt; 70 mg/dl as Determined by the CGM</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of BG Events &lt; 70 mg/dl as Determined by the CGM</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From the CGM Driving the Control Algorithm: o &lt; 70 mg/dl o 70-120 mg/dl o 70-180 mg/dl o &gt;180 mg/dl</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From the CGM Driving the Control Algorithm: o &lt; 70 mg/dl o 70-120 mg/dl o 70-180 mg/dl o &gt;180 mg/dl</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 70 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-120 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-180 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 180 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Dosing (u/kg)</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Dosing (u/kg)</title>
          <units>units/kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dextrose Dosing (g/kg)</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Dextrose Dosing (g/kg)</title>
          <units>grams/kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy of the CGM Device Using the GlucoScout Measurements as the Standard.</title>
        <description>The Mean Absolute Relative Difference (MARD) between CGM and Glucoscout</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed-loop Blood Glucose Control</title>
            <description>Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is &gt; 1 u/kg or &gt; 2 u/kg.
Closed-loop blood glucose control: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose &gt; 2 u/kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of the CGM Device Using the GlucoScout Measurements as the Standard.</title>
          <description>The Mean Absolute Relative Difference (MARD) between CGM and Glucoscout</description>
          <units>percent absolute relative difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Closed-loop Blood Glucose Control</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven J. Russell</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-8722</phone>
      <email>sjrussell@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

